Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2021;117:154373.
CAS
PubMed
Google Scholar
Pepper DJ, Demirkale CY, Sun J, Rhee C, Fram D, Eichacker P, et al. Does obesity protect against death in sepsis? A retrospective cohort study of 55,038 adult patients. Crit Care Med. 2019;47(5):643–50.
PubMed
PubMed Central
Google Scholar
Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128.
CAS
PubMed
Google Scholar
Anderson MR, Shashaty MGS. Impact of obesity in critical illness. Chest. 2021;160(6):2135–45.
CAS
PubMed
PubMed Central
Google Scholar
Erstad BL, Nix DE. Assessment of kidney function in patients with extreme obesity: a narrative review. Ann Pharmacother. 2021;55(1):80–8.
PubMed
Google Scholar
Chang A, Greene TH, Wang X, Kendrick C, Kramer H, Wright J, et al. The effects of weight change on glomerular filtration rate. Nephrol Dial Transplant. 2015;30(11):1870–7.
CAS
PubMed
PubMed Central
Google Scholar
Shashaty MG, Stapleton RD. Physiological and management implications of obesity in critical illness. Ann Am Thorac Soc. 2014;11(8):1286–97.
PubMed
PubMed Central
Google Scholar
Erstad BL. Improving medication dosing in the obese patient. Clin Drug Investig. 2017;37(1):1–6.
PubMed
Google Scholar
Domecq JP, Lal A, Sheldrick CR, Kumar VK, Boman K, Bolesta S, et al. Society of critical care medicine discovery viral infection and respiratory illness universal study (VIRUS): COVID-19 Registry Investigator Group. Outcomes of patients with coronavirus disease 2019 receiving organ support therapies: the international viral infection and respiratory illness universal study registry. Crit Care Med. 2021;49(3):437–48.
CAS
PubMed
Google Scholar
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed December 9, 2021.
Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. Crit Care. 2020;24(1):315. https://doi.org/10.1186/s13054-020-03040-z.
Article
PubMed
PubMed Central
Google Scholar
Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Crit Care. 2021;25(1):77. https://doi.org/10.1186/s13054-021-03495-8.
Article
PubMed
PubMed Central
Google Scholar
Erstad BL, Barletta JF. Dosing of neuromuscular blocking agents in patients with obesity: a narrative review. Anaesth Intensive Care. 2021;49(2):98–104. https://doi.org/10.1177/0310057X20968573.
Article
PubMed
Google Scholar
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017. https://doi.org/10.1093/nar/gkx1037.
Article
PubMed
PubMed Central
Google Scholar
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
Google Scholar
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–16.
CAS
PubMed
Google Scholar
COVID STEROID 2 Trial Group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA. 2021;326(18):1807–17.
Google Scholar
Lamiable D, Vistelle R, Sulmont V, Millart H, Caron J, Choisy H. Pharmacokinetics of dexamethasone administered orally in obese patients. Therapie. 1990;45(4):311–4.
CAS
PubMed
Google Scholar
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795–807.
CAS
PubMed
Google Scholar
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–18.
CAS
PubMed
PubMed Central
Google Scholar
Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 Inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104(2):364–73.
CAS
PubMed
Google Scholar
Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–15.
PubMed
Google Scholar
Xie R, Deng C, Wang Q, Kanik KS, Nicholas T, Menon S. Population pharmacokinetics of Tofacitinib in patients with psoriatic arthritis. Int J Clin Pharmacol Ther. 2019;57(9):464–73.
CAS
PubMed
PubMed Central
Google Scholar
Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, et al. Pharmacokinetic characteristics of Tofacitinib in adult patients with moderate to severe chronic plaque psoriasis. Clin Pharmacol Drug Dev. 2018;7(6):587–96.
CAS
PubMed
Google Scholar
Rubio-Rivas M, Forero CG, Mora-Luján JM, Montero A, Formiga F, Homs NA, et al. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis. Pharmacotherapy. 2021;41(11):884–906.
CAS
PubMed
PubMed Central
Google Scholar
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020;383(24):2333–44.
CAS
PubMed
Google Scholar
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32–40.
CAS
PubMed
Google Scholar
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–16.
CAS
PubMed
Google Scholar
Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511–21.
CAS
PubMed
PubMed Central
Google Scholar
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.
CAS
PubMed
Google Scholar
Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of Tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24–31.
CAS
PubMed
Google Scholar
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45.
Google Scholar
REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med. 2021;384(16):1491–502.
Google Scholar
Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021;47(11):1258–70.
CAS
PubMed
PubMed Central
Google Scholar
Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:84.
Google Scholar
Wang D, Fu B, Peng Z, Yang D, Han M, Li M, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021;15(3):486–94.
PubMed
PubMed Central
Google Scholar
Leung E, Crass RL, Jorgensen SCJ, Raybardhan S, Langford BJ, Moore WJ, et al. Pharmacokinetic/pharmacodynamic considerations of alternate dosing strategies of tocilizumab in COVID-19. Clin Pharmacokinet. 2022;61(2):155–65.
CAS
PubMed
Google Scholar
Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754–66.
CAS
PubMed
Google Scholar
Moes DJAR, van Westerloo DJ, Arend SM, Swen JJ, de Vries A, Guchelaar HJ, et al. Towards fixed dosing of Tocilizumab in ICU-admitted COVID-19 patients: results of an observational population pharmacokinetic and descriptive pharmacodynamic study. Clin Pharmacokinet. 2022;61(2):231–47.
CAS
PubMed
Google Scholar
Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, et al. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br J Clin Pharmacol. 2018;84(4):716–25.
CAS
PubMed
PubMed Central
Google Scholar
The REMAP-CAP Investigators, Lennie P.G. Derde. Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial. https://doi.org/10.1101/2021.06.18.21259133
Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):522–32.
CAS
PubMed
PubMed Central
Google Scholar
CORIMUNO-19 Collaborative group. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial. Lancet Rheumatol. 2022;4:e24–32.
Google Scholar
Xu C, Su Y, Paccaly A, Kanamaluru V. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis. Clin Pharmacokinet. 2019;58(11):1455–67.
CAS
PubMed
PubMed Central
Google Scholar
Ma L, Xu C, Paccaly A, Kanamaluru V. Population pharmacokinetic-pharmacodynamic relationships of sarilumab using disease activity score 28-Joint C-reactive protein and absolute neutrophil counts in patients with rheumatoid arthritis. Clin Pharmacokinet. 2020;59(11):1451–66.
CAS
PubMed
PubMed Central
Google Scholar
Kevzara [package insert]. Bridgewater, NJ: Sanofi and Regeneron Pharmaceuticals; 2018.
Remdesivir [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2021.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of covid-19—final report. N Engl J Med. 2020;383(19):1813–26.
CAS
PubMed
Google Scholar
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–57.
CAS
PubMed
Google Scholar
WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for covid-19—interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
Google Scholar
Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, et al. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with Remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021;73(11):2031–6.
CAS
PubMed
Google Scholar
Deb S, Reeves AA. Simulation of Remdesivir pharmacokinetics and its drug interactions. J Pharm Pharm Sci. 2021;24:277–91.
CAS
PubMed
Google Scholar